Advertisement
HQL or PBE or XBI
Which ETF would AI Choose? abrdn Life Sciences Investors (HQL) vs. Invesco Biotechnology & Genome ETF (PBE) vs. SPDR S&P Biotech ETF (XBI)
Key Takeaways
- HQL is a closed-end fund with an expense ratio of 1.24% and approximately 130-155 holdings focused on life sciences companies, offering active management but higher costs and potential premium or discount to net asset value.
- PBE tracks a dynamic Intellidex index with roughly 30-68 holdings, an expense ratio of 0.59%, and a concentrated, multi-factor approach to biotechnology and genome companies.
- XBI follows a modified equal-weighted S&P index with about 160 holdings, the lowest expense ratio at 0.35%, and broader diversification across the biotechnology sector.
- Structural differences in management style, concentration, and fees position XBI as the most cost-efficient and diversified option, while HQL and PBE emphasize more concentrated or actively selected exposures.
- All three funds target the biotechnology and life sciences theme, exposing investors to similar sector risks including regulatory changes, clinical trial outcomes, and innovation cycles.
- Relative positioning favors lower-cost, equal-weighted structures like XBI for risk-adjusted stability in volatile biotech markets over higher-fee or narrower portfolios.
Introduction
These three funds provide targeted exposure to the biotechnology and life sciences sector but employ distinct structural approaches. HQL operates as a closed-end fund with active selection, PBE uses a quantitative Intellidex methodology with fewer holdings, and XBI applies equal weighting across a broad index. Investors comparing them evaluate trade-offs in cost, diversification, and strategy within the same thematic universe rather than direct index competition.
abrdn Life Sciences Investors (HQL) Overview
HQL is a closed-end fund launched in 1992 with the objective of long-term capital appreciation through investments in U.S. and foreign life sciences companies, including biotechnology, pharmaceuticals, and medical equipment. It holds approximately 130-155 positions with top holdings typically including REGN, AMGN, and GILD. The fund maintains an expense ratio of 1.24% and features active management without a strict passive index. Sector allocation centers heavily on healthcare, particularly biotechnology, with some international exposure.
Invesco Biotechnology & Genome ETF (PBE) Overview
PBE seeks to track the Dynamic Biotech & Genome Intellidex Index, focusing on U.S. biotechnology and genome companies involved in research, development, and commercialization. It typically holds 30-68 securities with top positions such as BIIB, NTRA, and GILD. The expense ratio stands at 0.59%, and the fund employs a multi-factor selection process with quarterly rebalancing. Holdings emphasize companies benefiting from biotechnological advances, resulting in moderate concentration.
SPDR S&P Biotech ETF (XBI) Overview
XBI aims to replicate the S&P Biotechnology Select Industry Index through a modified equal-weighted approach across the biotechnology segment. It contains approximately 160 holdings with top weights generally around 1-2% each, including names like MRNA, NTRA, and AMGN. The expense ratio is 0.35%, the lowest among the group, and the structure supports broad diversification across market capitalizations with quarterly rebalancing.
Industry and Thematic Landscape
The biotechnology sector continues to experience capital allocation toward innovation in gene editing, oncology, and rare diseases amid evolving regulatory frameworks from agencies such as the FDA. Macroeconomic factors including interest rate environments influence funding for clinical-stage companies, while earnings trends among established players reflect pipeline successes and commercialization challenges. Geopolitical considerations around supply chains and intellectual property add complexity, and sector risks encompass high volatility from binary clinical outcomes and reimbursement pressures.
Performance and Positioning Comparison
In recent market cycles, equal-weighted structures like XBI have demonstrated lower concentration risk and more consistent participation across holdings compared to narrower portfolios. PBE's multi-factor methodology can lead to greater sensitivity to specific growth or momentum signals, resulting in variable drawdowns. HQL's closed-end structure introduces additional premium or discount dynamics that may amplify or dampen returns relative to underlying holdings. Differences arise primarily from weighting schemes and expense levels rather than short-term price fluctuations.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener for advanced filtering capabilities.
Tickeron AI Verdict
Based on observable structural characteristics, Tickeron’s AI would likely favor XBI with moderate probability due to its lower expense ratio, broader diversification across approximately 160 holdings, and modified equal-weighted methodology that supports more stable risk-adjusted positioning within the biotechnology theme compared to the higher-cost or more concentrated alternatives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HQL in +0.90% Uptrend, advancing for three consecutive days on October 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HQL advanced for three days, in 268 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HQL's RSI Indicator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for HQL just turned positive on October 20, 2026. Looking at past instances where HQL's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
HQL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HQL as a result. In 74 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 10-day moving average for HQL crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HQL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for HQL entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Momentum Indicator for PBE turns positive, indicating new upward trend
PBE saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 84 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PBE just turned positive on October 15, 2026. Looking at past instances where PBE's MACD turned positive, the stock continued to rise in 42 of 47 cases over the following month. The odds of a continued upward trend are 89%.
PBE moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PBE crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +2.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in 258 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 217 of 254 cases where PBE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
PBE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Momentum Indicator for XBI turns negative, indicating new downward trend
XBI saw its Momentum Indicator move below the 0 level on October 23, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 82 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 59 of 66 cases where XBI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
XBI moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XBI crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XBI just turned positive on October 21, 2026. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in 49 of 55 cases over the following month. The odds of a continued upward trend are 89%.
Following a +6.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 296 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
| HQL | PBE | XBI | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 82% | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 89% | 2 days ago 89% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 84% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 84% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 85% | 4 days ago 84% | 5 days ago 90% |
| Declines ODDS (%) | 11 days ago 85% | 2 days ago 79% | 2 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 90% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 85% | 2 days ago 90% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MATE | 31.33 | 0.07 | +0.23% |
| Man Active Trend Enhanced ETF (MATE) | |||
| UTF | 26.11 | 0.03 | +0.12% |
| Cohen & Steers Infrastructure Fund | |||
| IBD | 23.23 | -0.07 | -0.30% |
| Inspire Corporate Bond ETF (IBD) | |||
| DRES | 29.60 | -0.15 | -0.50% |
| GMO Domestic Resilience ETF (DRES) | |||
| WTID | 1.96 | -0.12 | -5.77% |
| MicroSectors Energy 3X Inverse Leveraged ETNs (WTID) | |||
HQL and
Correlation & Price change
A.I.dvisor indicates that over the last year, HQL has been loosely correlated with GH. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if HQL jumps, then GH could also see price increases.
| Ticker / NAME | Correlation To HQL | 1D Price Change % | ||
|---|---|---|---|---|
| HQL | 100% | -1.23% | ||
| GH - HQL | 36% Loosely correlated | +3.77% | ||
| ALNY - HQL | 28% Poorly correlated | -1.43% | ||
| AZN - HQL | 14% Poorly correlated | -0.63% | ||
| REGN - HQL | 4% Poorly correlated | -1.72% | ||
| SRPT - HQL | 2% Poorly correlated | -2.48% | ||
More | ||||